Introduction
Changes in gene expression, in both normal and malignant cells, are mediated by signal transduction pathways carrying information from the cell's environment to the nucleus. In cancer cells, Signal Transducer and Activator of Transcription 3 (Stat3) is among the most critical signal transducers regulating oncogenic gene expression. In response to cytokine or growth factor stimulation, Stat3 is phosphorylated on tyrosine 705 (pY-Stat3), resulting in dimerization, nuclear translocation, and binding to DNA regulatory elements. Stat3 also is phosphorylated on serine 727 (pS-Stat3), which may augment transactivation 1 . Stat3 targets include anti-apoptosis genes, cell cycle regulators, and angiogenesis factors. Increased Stat3 activity in leukemia cells contributes to therapy resistance 2, 3 . Thus, it is no surprise that aberrant Stat3 activity is associated with more aggressive disease across a variety of malignancies [4] [5] [6] .
In acute myeloid leukemia (AML), increased constitutive pY-Stat3, as detected by
Western blot or electrophoretic mobility shift assay (EMSA,) has been reported in 21-76% of adult patients 4, [7] [8] [9] [10] , and was associated with shorter time to relapse 4 . Likewise, increased constitutive pY-Stat5, as is reported with the FLT3 internal tandem duplication (FLT3/ITD), is associated with poor outcome 11, 12 . More recently, we and others have measured phosphorylated
Stat proteins in AML samples by intracellular flow cytometry (phospho-flow) [13] [14] [15] [16] [17] . This highly sensitive method yields quantitative information at the single cell level.
We undertook a comprehensive analysis of Stat3 and Stat5 signaling patterns in a large cohort of primary pediatric AML samples from the Children's Oncology Group (COG). We measured both constitutive and ligand-induced pY-Stat3, pS-Stat3 and pY-Stat5. We further identified specific patterns of constitutive and ligand-induced Stat3/5 activation, and correlated these patterns with the expression of various upstream and downstream regulators of Stat3/5
For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From activity, including pY418-Src, surface G-CSF receptor and gp130 expression, SOCS3, and SHP1. Among all the signaling parameters measured, we found that the sensitivity of the pYStat3 response to G-CSF and IL-6 stimulation correlated with event-free and overall survival.
Thus, while much information exists regarding gene expression and mutation profiles and AML prognosis, this is the first comprehensive analysis of functional signaling activities in pediatric AML and their potential roles in clinical outcome.
Methods and Materials

Cells
Cryopreserved bone marrow samples from 175 pediatric patients with de novo AML were obtained from the Children's Oncology Group (COG) AML Reference Lab. All were enrolled on the treatment protocol CCG 2961 and gave written informed consent, in accordance with the Declaration of Helsinki, for banking of bone marrow for future research. The treatment regimen and outcomes for this study have been reported 18 . Consecutive samples with multiple vials in the Reference Bank were selected. Bone marrow samples were enriched for mononuclear cells by density centrifugation and cryopreserved.
Normal bone marrow (NBM) was obtained from healthy individuals donating bone marrow for patients at Texas Children's Hospital, under an IRB-approved protocol for the use of anonymized remainder tissue. No identifying information or clinical data were collected for these donors. Leftover bone marrow cells were obtained by rinsing the collection filter after the marrow had been removed for clinical processing. Mononuclear cells were enriched by density centrifugation and cryopreserved.
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The human AML cell line Kasumi-1 was used as the positive control for all flow cytometry studies, and as the inter-blot reference for the immunoblot studies. Kasumi-1 cells were obtained from American Type Culture Collection (ATCC, Manassas, VA), and grown in RPMI (ATCC) with 10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA), and 100 units/ml penicillin and 100 μg/ml streptomycin (pen/strep; Invitrogen). Kasumi-1 cells were grown in a humidified, 37º C incubator with 5% CO 2 . These studies were approved by the Institutional Review Board of Baylor College of Medicine.
Flow Cytometry
Samples were thawed into Iscove's Modified Dulbecco's Medium (IMDM; HyClone, Logan, UT) with 10% FBS, washed once in IMDM + 10% FBS to remove residual DMSO, then resuspended in serum-free StemSpan H3000 (StemCell Technologies, Vancouver, BC) and rested for 2 hr. Cell viability after the rest period was determined by Trypan Blue dye exclusion.
Twenty-six samples with viability <75% were not processed further, and ten samples were excluded for insufficient cell number or other technical reasons. Ultimately, 139 samples were suitable for analysis. Age of the sample was not found to be a factor in cell viability. Cells were distributed at 2-3 x 10 5 cells/well in 10 aliquots. Four aliquots remained unstimulated; 3 were stimulated with granulocyte-colony stimulating factor (G-CSF; Filgrastim, Amgen, Thousand
Oaks, CA) at 1 ng/ml, 10 ng/ml, and 100 ng/ml, and 3 were stimulated with interleukin-6 (IL-6; BD Pharmingen, San Diego, CA) + soluble IL-6 receptorα (sIL-6R; R&D Systems, Minneapolis, MN) at 0.5 + 1 ng/ml, 5 + 10 ng/ml, and 50 + 100 ng/ml, respectively. When sufficient, remaining cells were used for Western blots. Kasumi-1 cells were used as positive controls for G-CSF and IL-6 activity. They were removed from serum-containing medium and rested in serum-free StemSpan H3000 for 2 hr, then processed simultaneously with the patient samples. Cells were divided into 4 aliquots for the isotype control, unstimulated pStats, G-CSF-induced pStats, and IL-6-induced pStats. Only the highest doses (dose level 3) were tested for the Kasumi-1 cells. Results of these control assays are presented in Supplemental Figure 1 .
Western blot
Whole cell lysates were prepared and immunoblots were performed as described 14 .
Primary antibodies against human SOCS3 and SHP1 were purchased from Abcam. Bands were directly detected on an Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NE).
Densitometry analysis was done with Image J (NIH). Each densitometric value was normalized to the corresponding β-actin value. To account for differences in exposures between blots, each normalized value from an AML sample was divided by the normalized value from Kasumi-1 lysate run on the same gel.
Statistics
Median values of signaling parameters between AML and normal bone marrow (NBM)
samples were compared by the Mann-Whitney U test. Spearman rank correlations were used to assess relationships between two continuous variables (SPSS v. 19). Given a sample size of 139 and two-sided alpha error of 0.05, this study had 80% power to detect a correlation of R=0.234 or higher. The significance of observed differences in proportions was tested using the Chisquared test and Fisher's exact test when data were sparse. Data were analyzed through November 6, 2009 for patients enrolled on CCG 2961. Estimates of the distributions of eventfree (EFS) and overall survival (OS) from study entry were calculated by the Kaplan-Meier method. Estimates are reported with 95% confidence intervals (CI) that were computed using a log (-log) transformation. OS is defined as time from study entry to death from any cause. EFS is defined as time from study entry to induction failure, relapse or death from any cause. EFS and OS were compared for significant differences by the log-rank test. The Cox proportional hazards model was used to estimate hazard ratios (HR) and to determine the prognostic value of where the proportion of patients in one group is 10% and 50%, respectively. This study also had 80% power to detect OS HR of 0.28 and 0.49 between two groups where the proportion of patients in one group is 10% and 50%, respectively.
Results
Unstimulated Stat3/5 pathway parameters
One hundred thirty-nine primary samples from patients enrolled on the Children's Cancer Group CCG 2961 study were analyzed. The characteristics of this cohort, relative to the other patients enrolled on the study, are shown in Table 1 . The inclusion of a higher number of older patients and patients with higher presenting WBC, compared to the unstudied patients, likely reflects the selection of samples with multiple vials in the COG AML Reference Bank, and has been reported previously 19 . There were no significant differences in remission or survival rates between patients included in this study and those who were not. Unstimulated AML cells were examined by FACS for baseline levels of pY-Stat3, pS-Stat3 and pY-Stat5. Constitutive pY418-Src, total Stat3, G-CSF receptor (G-CSFR), and IL-6 receptor (gp130) also were measured by FACS. All samples were gated on the blast population. After establishing the negative region with isotype control antibodies, the percent of positive events was measured for each sample and antigen ( Figure 1A ). We measured the same parameters, with similar gates, in 9 normal bone marrow (NBM) mononuclear cell samples for comparison.
We found that constitutive pY-Stat3 and pY-Stat5 are common, and in some cases quite elevated, whereas constitutive pS-Stat3 is rare. Most AML samples had low levels of constitutive Src activation, but there was a distinct population of samples with increased basal pY418-Src, up to 40% (Supplemental Figure 2A) . For the 98 samples with sufficient remaining material, we performed Western blotting to determine the levels of two important negative regulators of Stat3/5 signaling in hematopoietic cells -the Jak inhibitor SOCS3 and the tyrosine phosphatase SHP1. We found that SOCS3 expression was quite low in most AML and NBM samples ( Figure 2D ). In contrast, SHP1 was 
Inducible pStats
To test the potential for activation of the Stat3 and Stat5 pathways by exogenous stimuli, we treated AML cells with two factors that regulate normal myelopoiesis and signal through Stat3: G-CSF and IL-6. To determine the sensitivity of the pathways to each ligand, we tested three dose levels: 1, 10, and 100 ng/ml G-CSF, and 0.5 + 1, 5 + 10, and 50 + 100 ng/ml IL-6 + sIL-6R, respectively. We calculated the fold change in the mean fluorescence intensity (ΔMFI) between the unstimulated and stimulated conditions, and defined a response as a ΔMFI of at least 2 (log 2 (ΔMFI)≥1).
Seventy of 132 (53%) primary samples responded to G-CSF with increased pY-Stat3, and 52/116 (45%) responded with increased pY-Stat5 ( Figure 3A ). Forty-seven percent and 55% of samples failed to respond with increased pY-Stat3 or pY-Stat5, respectively, even at the highest dose of G-CSF (Table 3 ). Failure to respond was not associated with the age of the sample, the %viability (75-100%), or the %blasts (prior to mononuclear cell enrichment). Only 3 or fewer samples had a log 2 (ΔMFI)≥1 in response to the lowest dose of ligand ( Figure 3B -C).
The pY-Stat3 log 2 (ΔMFI) ranged from 0 (no change) to 3.62, and the maximum log 2 (ΔMFI) for pY-Stat5 was 4.54. Stat3 serine phosphorylation was less frequent and less robust; the maximum log 2 (ΔMFI) for pS-Stat3 was 2. We also determined ligand responses of 8 NBM samples to G-CSF and IL-6. In contrast to the variable responses in the AML samples, the responses in the normal samples were quite consistent. In 7/8 cases, we noted a subpopulation, comprising 6-40% of the nonlymphocyte mononuclear cells, that showed several-fold increases in all three pStats in response to G-CSF, and in pY-and pS-Stat3 in response to IL-6, at the intermediate and high doses (data not shown).
This robust response within a subset of the myeloid precursor population is consistent with other recent studies 20, 21 .
Relationships between signaling parameters
To identify patterns of relationship between the various parameters, we performed
Spearman correlations. Figure 
Correlations of Signaling Parameters with Clinical Parameters
For the basal pStat parameters, total Stat3, pY418-Src, and receptor levels, we performed cut-point analyses using all values between the 10 th and 90 th percentiles, to determine whether a threshold separating favorable outcome and poor outcome could be identified. No such threshold was found for pY-Stat3 (Supplemental Figure 5A ), total Stat3 (Supplemental Figure   5B ) or any of the other basal parameters. Cut-point analyses also were applied to the magnitude of the ligand-induced pStat responses (i.e. maximum log 2 (ΔMFI)), and similarly, no prognostic response magnitude was identified. Thus, in this study, neither constitutive nor induced pStat levels correlated with survival.
In contrast, evaluation of G-CSF-induced pY-Stat3 activation showed a significant association of ligand sensitivity with clinical outcome ( Figure 5A ). Patients whose blasts had a pY-Stat3 response (i.e. log 2 (ΔMFI)≥1) to G-CSF at dose level 2 (10 ng/ml; n=44, 33%) had a 5- as the clinically relevant threshold (Supplemental Figure 6) . A similar trend was observed for pY-Stat3 sensitivity to IL-6 at dose level 2 (not shown, p=0.114 for EFS and p=0.058 for OS).
Despite the strong correlation between the magnitudes of G-CSF-induced pY-Stat3 and pYStat5, we did not find a significant relationship between the pY-Stat5 sensitivity to G-CSF and outcome. Of the 44 samples with a pY-Stat3 response to G-CSF at dose level 2, 12 did not meet the "response" threshold at this dose for pY-Stat5, and 5 others were not analyzed for pY-Stat5.
Next, we asked whether combining G-CSF and IL-6 sensitivities correlated with survival.
To do so, we classified samples into four groups. Group SS (n=15, 11%) samples were sensitive to both G-CSF and IL-6, meaning they achieved ΔMFI ≥ 2 (log 2 (ΔMFI) ≥ 1) for pY-Stat3 at dose level 2 for both ligands. Group SR (n=28, 21%) samples were sensitive to G-CSF but resistant to IL-6, and Group RS (n=7, 5%) included samples that were resistant to G-CSF but sensitive to IL-6. The majority of samples were resistant to both ligands and thus were classified as Group RR (n=81, 61%). Figure 5B shows the EFS and OS for each group. Group SS patients had a These results support the conclusion that the SS response pattern was a true favorable prognostic factor in this study.
Current risk stratification schemes for pediatric AML rely heavily on cytogenetic findings and the presence or absence of FLT3/ITD, CEBPα, and NPM1 mutations. Therefore, we asked whether there were any associations between the pY-Stat3 response groups and these parameters. Cytogenetic results are available for 92/139 (66%) of the patients in this cohort.
FLT3/ITD and CEBPα mutation results are known for 92% of patients, and NPM1 mutation status is known for 73%. Table 5 shows that the G-CSF sensitive group included a significantly higher proportion of patients with core binding factor translocations, compared to the G-CSF Thus, by phospho-flow, we did not find a significant difference in constitutive pY-Stat3 or pYStat5 between AML and NBM cells, nor were these parameters associated with survival.
Flow cytometry also allows multiple parameters to be measured in each patient sample.
Bivariate correlations identified relationships between parameters that provided new insights into
Stat3/5 signaling in AML. For example, we found only a weak relationship between constitutive pY-Stat3 and pY-Stat5, but an extremely tight correlation between these parameters after G-CSF stimulation. These results suggest that the mechanisms leading to constitutive activation are
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Correlations between surface markers and pStats also yielded interesting results. While the relationship between G-CSFR expression and G-CSF-induced pY-Stat3 was a positive one, we did identify a number of samples with high G-CSFR expression that failed to induce pYStat3. Even more striking, the relationship between gp130 expression and IL-6-induced pYStat3 was inverse. The disconnect between the receptor at the surface and the pY-Stat3 target could occur at several levels. For example, mislocalization of receptors, e.g. outside lipid raft domains, could explain the high level of non-functioning receptors we see in some cases.
Alternatively, an element in the pathway between the receptor and Stat3, such as a Jak or Src kinase, could be dysfunctional. Bivariate correlations also allowed us to define a signaling pattern that was associated with CD33 expression, and possibly therefore, with the degree of myeloid maturation. That is, samples with higher CD33 expression had higher constitutive pYStat5 levels, higher gp130 expression, and lower IL-6 responsiveness.
Our study is the first to identify an association between the sensitivity of a signaling pathway and patient survival in AML. Recent phospho-flow studies using adult AML samples have found an association between increased basal and induced pY-Stat3 and decreased likelihood of achieving remission 13, 15 . We did not find an association between the magnitude of basal or induced pStats and clinical outcome. Our data instead revealed a significant association between the sensitivity of the ligand response and outcome, with increased sensitivity being significantly associated with better survival. These observed differences may be due in part to the different study populations. It is well recognized that pediatric AML is biologically different from its adult counterpart, with distinct cytogenetic and molecular characteristics. Our data further suggest there may be fundamental biologic differences.
While the pY-Stat3 response to G-CSF alone was prognostic, even more definitive stratification was obtained when both ligands were taken into account. It is important to note that patients with a favorable response pattern were more likely to also have low risk cytogenetics, and the limited availability of cytogenetic data in the CCG 2961 study precluded meaningful multivariate analysis. Interestingly, however, low risk cytogenetics did not emerge as a significant favorable predictor by univariate analysis in this cohort, while the Group SS response pattern was significant. It remains to be determined whether ligand responsiveness will become a useful criterion for risk assessment, but our data do suggest that it may be of value, at least in cases that lack other strong predictors such as FLT3/ITD or CEBPα mutations.
The RS pattern suggests that signaling pathways in general may be intact, but that these samples may have a specific defect within or proximal to the G-CSFR. In support of this idea, with worse outcome in patients who received G-CSF. Our results also have implications for the use of G-CSF "priming" in AML. The theory is that G-CSF pre-treatment sensitizes blasts to chemotherapy. Our finding that nearly half of the samples failed to respond to G-CSF may be one explanation for the variable results with this approach, and evaluation of G-CSF-induced pY-Stat3 may be one way to identify patients who are likely to benefit from a priming strategy.
Indeed, erythropoietin-induced Stat5 phosphorylation correlates with clinical erythropoietin response in patients with myelodysplastic syndromes, and it has been suggested that this assay could be used as a screening test to predict whether a patient is likely to benefit from treatment 27 .
Ligand-response information also could be used to identify patients who are, and are not, DJT designed the study and wrote the manuscript. SM provided the samples, designed the study, and wrote the manuscript.
Conflict of Interest Disclosures
None of the authors has any conflicts to disclose. 2008;32(6):893-903.
For 
